FDA Greenlights Home-Administered Initial Dosing for Leqembi in Alzheimer’s Treatment

The U.S. Food and Drug Administration (FDA) has approved a new subcutaneous starting dosage regimen for lecanemab (Leqembi Iqlik), expanding treatment options for adults with Alzheimer’s disease. Previously authorized only as an intravenous (IV) infusion with later transitions to subcutaneous maintenance dosing, this updated approval enables patients to initiate therapy at home under self-administration or caregiver supervision.

Lecanemab, an anti-amyloid monoclonal antibody approved in 2023, targets early-stage Alzheimer’s by reducing cognitive and functional decline, as demonstrated in the Phase III CLARITY AD trial. However, the study also identified significant adverse effects, including amyloid-related imaging abnormalities (ARIA) with edema (ARIA-E) in 13% of participants and hemorrhagic manifestations (ARIA-H) in 17%. Individuals with APOE4 homozygous variants, cerebral amyloid angiopathy, or those on anticoagulants face elevated ARIA risk.

The FDA mandates a boxed warning to highlight these risks and recommends pre-treatment APOE4 testing. While the subcutaneous formulation was not individually tested in large trials, its efficacy is supported by IV data showing equivalent outcomes. Drugmakers Eisai and Biogen reported comparable rates of exposure-related adverse events between administration methods, with injection-site reactions like redness and swelling noted in the subcutaneous group.

Common side effects include headaches and mild local reactions. The drug carries a contraindication for patients with known hypersensitivity. This approval follows the 2025 authorization of subcutaneous maintenance dosing, streamlining long-term management of Alzheimer’s disease for eligible individuals.

Source link